JP2025509390A5 - - Google Patents
Info
- Publication number
- JP2025509390A5 JP2025509390A5 JP2024553723A JP2024553723A JP2025509390A5 JP 2025509390 A5 JP2025509390 A5 JP 2025509390A5 JP 2024553723 A JP2024553723 A JP 2024553723A JP 2024553723 A JP2024553723 A JP 2024553723A JP 2025509390 A5 JP2025509390 A5 JP 2025509390A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- caliprazine
- composition according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320706P | 2022-03-17 | 2022-03-17 | |
| US63/320,706 | 2022-03-17 | ||
| PCT/IL2023/050150 WO2023175598A1 (en) | 2022-03-17 | 2023-02-14 | Depot systems comprising cariprazine or salts thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509390A JP2025509390A (ja) | 2025-04-11 |
| JP2025509390A5 true JP2025509390A5 (https=) | 2026-02-24 |
Family
ID=88022782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553723A Pending JP2025509390A (ja) | 2022-03-17 | 2023-02-14 | カリプラジン又はその塩を含むデポシステム |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11931357B2 (https=) |
| EP (1) | EP4493274A4 (https=) |
| JP (1) | JP2025509390A (https=) |
| CN (1) | CN119136804A (https=) |
| AU (1) | AU2023234747A1 (https=) |
| CA (1) | CA3244202A1 (https=) |
| IL (1) | IL315074A (https=) |
| MX (1) | MX2024011063A (https=) |
| WO (1) | WO2023175598A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| AU2023234747A1 (en) * | 2022-03-17 | 2024-09-12 | Mapi Pharma Ltd. | Depot systems comprising cariprazine or salts thereof |
| US20230372331A1 (en) * | 2022-05-18 | 2023-11-23 | Anxo Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| CN119424341A (zh) * | 2023-08-02 | 2025-02-14 | 珠海市华海康医药科技有限责任公司 | 一种注射用药物缓释微球及其制备方法 |
| CN117137864A (zh) * | 2023-11-01 | 2023-12-01 | 山东则正医药技术有限公司 | 一种卡利拉嗪原位凝胶制剂及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| US20090036468A1 (en) * | 2007-08-03 | 2009-02-05 | Forest Laboratories Holdings Limited | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
| US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| WO2018015915A1 (en) * | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN108261394B (zh) | 2017-01-04 | 2022-03-04 | 广东东阳光药业有限公司 | 一种盐酸卡利拉嗪注射制剂及其制备方法和用途 |
| HUP1700253A1 (hu) | 2017-06-13 | 2019-01-28 | Richter Gedeon Nyrt | Szilárd orális gyógyszerkészítmények |
| US11344503B2 (en) * | 2019-12-13 | 2022-05-31 | Halo Science LLC | Cariprazine release formulations |
| WO2022003662A1 (en) | 2020-06-29 | 2022-01-06 | Mapi Pharma Ltd. | Low burst-release liraglutide depot systems |
| AU2023234747A1 (en) * | 2022-03-17 | 2024-09-12 | Mapi Pharma Ltd. | Depot systems comprising cariprazine or salts thereof |
-
2023
- 2023-02-14 AU AU2023234747A patent/AU2023234747A1/en active Pending
- 2023-02-14 MX MX2024011063A patent/MX2024011063A/es unknown
- 2023-02-14 US US18/109,328 patent/US11931357B2/en active Active
- 2023-02-14 JP JP2024553723A patent/JP2025509390A/ja active Pending
- 2023-02-14 CN CN202380028161.9A patent/CN119136804A/zh active Pending
- 2023-02-14 WO PCT/IL2023/050150 patent/WO2023175598A1/en not_active Ceased
- 2023-02-14 CA CA3244202A patent/CA3244202A1/en active Pending
- 2023-02-14 EP EP23770030.7A patent/EP4493274A4/en active Pending
- 2023-02-14 IL IL315074A patent/IL315074A/en unknown
-
2024
- 2024-02-08 US US18/436,682 patent/US12251380B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025509390A5 (https=) | ||
| KR101944367B1 (ko) | 부프레노르핀 운반용 약물남용 억제 점막 부착 장치 | |
| JP7751638B2 (ja) | ガンマ－ヒドロキシ酪酸誘導体の調節放出組成物 | |
| KR20140088236A (ko) | 경구 투여용 코르티코스테로이드 조성물 | |
| EP3287438A1 (en) | Choline salt of an anti-inflammatory substituted cyclobutenedione compound | |
| CN103976968A (zh) | 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法 | |
| JP7126260B2 (ja) | 治療処置用の口腔粘膜ナノファイバ担体 | |
| JP7702950B2 (ja) | アゴメラチンを含有する経粘膜治療システム | |
| US20250073170A1 (en) | High concentration formulations of anti-csf1 and anti-csf1r antibodies | |
| CN110072520A (zh) | 新型替比培南匹伏酯速释和调释口服剂型 | |
| CN117561082A (zh) | 治疗重症抑郁和难治性抑郁的方法 | |
| US20220401389A1 (en) | Transmucosal therapeutic system containing agomelatine | |
| JP2012111773A (ja) | 経口吸収改善用医薬組成物 | |
| WO2022115056A1 (en) | Sustained release formulation compositions comprising propiverine | |
| TWI897768B (zh) | 阿哌沙班膜產品用於治療血栓症之用途 | |
| CN112672743A (zh) | 肝病瘙痒症状的治疗 | |
| EP3796908A1 (en) | Controlled release propiverine formulations | |
| TWI918360B (zh) | 納洛酮口頰膜製劑及其用途 | |
| TW202539667A (zh) | 納洛酮口頰膜製劑及其用途 | |
| HK40116297A (zh) | 包含卡利拉嗪或其盐的储库系统 | |
| WO2022229982A1 (en) | Oral formulations of edaravone and method of manufacturing thereof | |
| HK40126453A (zh) | γ-羟基丁酸衍生物的修饰释放组合物 | |
| AU2017251803B2 (en) | Choline salt of an anti-inflammatory substituted cyclobutenedione compound | |
| HK40087326B (zh) | γ-羟基丁酸衍生物的修饰释放组合物 | |
| HK40087326A (zh) | γ-羟基丁酸衍生物的修饰释放组合物 |